Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKY2: Aganirsen eye drops to extend aflibercept interval in wet AMD
2026-526775-27-00Phase 2Authorised
- Sponsor
- Laboratoires Kol
- Start
- Aug 2026
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in exudative macular degeneration comparing Aganirsen + aflibercept T&E with Placebo + aflibercept T&E (2 arms). Primary endpoint: Successful extension of aflibercept interval by ≥2 weeks at 9 months. Planned start Aug 2026; status: authorised.
02
Drugs
aganirsen
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2026-526775-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526775-27-00.